Why Illumina (ILMN) Stock Is Down Today

Illumina (ILMN) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a new patent setback in Germany involving Element Biosciences. With no new Illumina operating update released today beyond its planned July 30, 2026 earnings date, investors may be reacting to the legal overhang and the possibility of added pressure on sequencing-system sales in that market.

Details:

Element Biosciences announced on July 14, 2026 that a Munich court ruled Illumina and its German subsidiary infringed patent rights tied to an imaging method used in DNA sequencing.

The ruling said Illumina was liable for direct and indirect infringement connected to sequencing systems and related consumables, which raises concern about possible business disruption in Germany.

Illumina’s own investor update from July 9 only scheduled second-quarter 2026 results for July 30, with no fresh guidance change or new commercial announcement to offset the legal news.

Illumina’s last reported quarterly results had kept its 2026 revenue growth outlook unchanged, so today’s drop looks more tied to litigation risk than to a newly disclosed deterioration in core fundamentals.

Sources:

Element Biosciences, Illumina investor relations, SEC filings

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ILMN Insider Trading Activity

$ILMN insiders have traded $ILMN stock on the open market 42 times in the past 6 months. Of those trades, 1 have been purchases and 41 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by insiders over the last 6 months:

KEITH A. MEISTER has made 0 purchases and 26 sales selling 999,056 shares for an estimated $154,974,605.
PATRICIA LECKMAN (SVP, Chief People Officer) has made 0 purchases and 9 sales selling 3,937 shares for an estimated $529,719.
SCOTT M DAVIES (Chief Legal Officer) has made 0 purchases and 3 sales selling 2,566 shares for an estimated $364,316.
SCOTT D ERICKSEN (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,000 shares for an estimated $305,150.
CHRISTENSEN JAKOB WEDEL (SVP, Strategy/Corp Development) sold 700 shares for an estimated $97,328
SCOTT GOTTLIEB purchased 200 shares for an estimated $23,562

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ILMN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ILMN Hedge Fund Activity

We have seen 342 institutional investors add shares of $ILMN stock to their portfolio, and 380 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 4,551,213 shares (-22.6%) from their portfolio in Q1 2026, for an estimated $560,982,514
WCM INVESTMENT MANAGEMENT, LLC added 1,851,848 shares (+45.5%) to their portfolio in Q1 2026, for an estimated $228,258,784
LOOMIS SAYLES & CO L P removed 1,228,743 shares (-29.5%) from their portfolio in Q1 2026, for an estimated $151,454,862
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. added 863,721 shares (+inf%) to their portfolio in Q1 2026, for an estimated $106,462,250
ALLIANCEBERNSTEIN L.P. added 854,747 shares (+360.9%) to their portfolio in Q1 2026, for an estimated $105,356,115
JUPITER ASSET MANAGEMENT LTD added 816,436 shares (+300.9%) to their portfolio in Q1 2026, for an estimated $100,633,901
BLACKROCK, INC. added 701,913 shares (+3.8%) to their portfolio in Q1 2026, for an estimated $86,517,796

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ILMN Government Contracts

We have seen $31,087,575 of award payments to $ILMN over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ILLUMINA DRAGEN GENOMIC ANALYSIS SYSTEM: $1,189,411
ILLUMINA REAGENTS AND CONSUMABLES: $999,049
PURCHASE OF 7 MISEQ I100S TO PERFORM WHOLE GENOME SEQUENCING (WGS) ON ALL FOODBORNE PATHOGENS ISOLATED AND ...: $805,796
ILLUMINA REAGENT CHEMISTRY KITS: $684,263
ILLUMINA REAGENTS AND CONSUMABLES, EO 14398: $650,392

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ILMN Congressional Stock Trading

Members of Congress have traded $ILMN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ILMN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 02/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ILMN Analyst Ratings

Wall Street analysts have issued reports on $ILMN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Stifel issued a "Buy" rating on 01/20/2026

To track analyst ratings and price targets for $ILMN, check out Quiver Quantitative's $ILMN forecast page.

$ILMN Price Targets

Multiple analysts have issued price targets for $ILMN recently. We have seen 10 analysts offer price targets for $ILMN in the last 6 months, with a median target of $177.5.

Here are some recent targets:

Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
David Westenberg from Piper Sandler set a target price of $200.0 on 07/01/2026
Subbu Nambi from Guggenheim set a target price of $200.0 on 06/29/2026
Eve Burstein from Bernstein set a target price of $185.0 on 06/26/2026
Luke Sergott from Barclays set a target price of $145.0 on 06/24/2026
Casey Woodring from JP Morgan set a target price of $185.0 on 06/10/2026
Dan Leonard from RBC Capital set a target price of $170.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.